サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1611039

抗血管内皮増殖因子治療の市場規模、シェア、動向分析レポート：製品別、疾患別、地域別、セグメント予測、2025年～2030年

Anti-vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
抗血管内皮増殖因子治療の市場規模、シェア、動向分析レポート：製品別、疾患別、地域別、セグメント予測、2025年～2030年
出版日: 2024年11月21日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗血管内皮増殖因子治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の抗血管内皮増殖因子治療市場規模は2030年までに129億米ドルに達し、予測期間中のCAGRは-2.35%になると予測されています。

新薬開発を促進するための抗VEGF治療の研究開発に対する資金提供の増加は、市場成長を加速させると予想されます。さらに、眼科疾患を発症しやすい高齢者の増加と相まって、新規の革新的な製品の採用が、予測期間中の市場成長を促進すると期待されています。

国連経済社会局のデータによると、2019年の世界の高齢者（60歳以上）は約7億300万人でした。65歳以上人口の割合は6％で、2019年には9％に増加しました。高齢化人口を国別に見ると、2017年にはアフリカで約6,870万人、アジアで約5億4,920万人、欧州で約1億8,300万人、北米で約7,840万人、ラテンアメリカ＆その他の中東・アフリカで7,600万人以上でした。したがって、高齢者の増加が市場を牽引すると予想されます。

開発途上地域には償還施策がないため、費用対効果の高い新規分子を求める機会が生まれています。さらに、眼科医はより効果的な新薬に切り替えるため、企業は産業の地位を維持するために研究開発への投資を余儀なくされています。既存薬のバイオシミラーに対する研究者の関心は、抗VEGF治療のパイプラインにおける主要な動向です。

さらに、各社はこれらの治療の採用を増やす可能性のある様々な製剤やドラッグデリバリーシステムを開発しています。例えば、F. Hoffmann-La Roche Ltd.はポートデリバリーシステム-RG6321（ラニビズマブ）を開発しており、現在第III相臨床検査中です。これは、詰め替え可能な眼インプラントで、カスタマイズ型製剤のラニビズマブを数ヶ月にわたって持続的に投与するものです。

特許保護の喪失は市場成長に悪影響を及ぼす可能性が高く、主要企業は新たな収益源を検討するようになりました。しかし、その結果、バイオシミラー医薬品の生産者にとっては新興市場が形成されつつあります。こうした競合の激化が市場成長の妨げになると予想されます。しかし、競争優位性のある新規製品の発売により、予測期間中は抑制の影響は小さくなると予想されます。

抗血管内皮増殖因子治療市場のレポートハイライト

  • 2024年には、加齢黄斑変性（AMD）が最大の収益シェアを占め、予測期間中もその優位性を維持すると予測されます。
  • 2024年の製品別市場シェアはEyleaが61.9%で最大となっています。Eylea（aflibercept）はRegeneron PharmaceuticalsがBayerと共同開発した抗VEGF治療で、湿性加齢黄斑変性（AMD）、糖尿病黄斑浮腫（DME）、網膜静脈閉塞症（RVO）などの網膜疾患の治療として第一人者となっています。
  • 北米の抗血管内皮増殖因子治療市場は世界産業を支配し、2024年には売上シェアの65.71%を占めました。これは、加齢黄斑変性（AMD）、糖尿病網膜症、網膜静脈閉塞症、黄斑浮腫などの眼関連疾患の有病率が増加していることに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗血管内皮成長因子治療市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場展望
    • 関連/付随市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 抗血管内皮成長因子治療市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析

第4章 抗血管内皮成長因子治療市場：製品別、推定・動向分析

  • セグメントダッシュボード
  • 抗血管内皮成長因子治療市場：製品変動分析
  • 抗血管内皮成長因子治療市場：製品別展望
  • 2018～2030年の市場規模と予測と動向分析
  • アイレア
  • ルセンティス
  • ベオヴ
  • ヴァビスモ
  • その他

第5章 抗血管内皮成長因子治療市場：疾患別、推定・動向分析

  • セグメントダッシュボード
  • 抗血管内皮成長因子治療市場：疾患変動分析
  • 抗血管内皮成長因子治療市場：疾患別展望
  • 2018～2030年の市場規模と予測と動向分析
  • 黄斑浮腫
  • 糖尿病網膜症
  • 網膜静脈閉塞症
  • 加齢黄斑変性症
  • 近視性脈絡膜新生血管

第6章 抗血管内皮成長因子治療市場：地域別、推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 企業分類
  • 主要市場参入企業による最近の動向と影響分析
  • 企業市場シェア分析、2024年
  • 企業概要
    • Regeneron Pharmaceuticals, Inc.
    • Bayer AG
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Biogen
    • Pfizer, Inc.
    • Coherus BioSciences, Inc.
    • Amgen, Inc.
    • Bausch Health Companies, Inc.
    • Viatris, Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 5 North America anti-vascular endothelial growth factor therapeutics, by region, 2018 - 2030 (USD Billion)
  • Table 6 North America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 7 North America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 8 U.S. anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 9 U.S. anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 10 Canada anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 12 Mexico anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 13 Mexico anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 14 Europe anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 15 Europe anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 16 Europe anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 17 UK anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 18 UK anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 19 Germany anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 20 Germany anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 21 France anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 22 France anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 23 Italy anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 24 Italy anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 25 Spain anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 26 Spain anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 27 Denmark anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 28 Denmark anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 29 Norway anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 30 Norway anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 31 Sweden anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 32 Sweden anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 36 Japan anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 37 Japan anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 38 China anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 39 China anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 40 India anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 41 India anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 42 Australia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 43 Australia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 44 South Korea anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 45 South Korea anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 46 Thailand anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 47 Thailand anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 48 Latin America anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 49 Latin America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 50 Latin America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 51 Brazil anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 52 Brazil anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 53 Argentina anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 54 Argentina anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 55 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 56 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 57 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 58 South Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 59 South Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 60 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 62 UAE anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 63 UAE anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Anti-vascular endothelial growth factor therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and disease segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Parent market value, 2024 (USD Billion)
  • Fig. 12 Market dynamics
  • Fig. 13 Prevalence of diabetic retinopathy in the U.S. in 2021
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Anti-vascular endothelial growth factor therapeutics market: Product outlook and key takeaways
  • Fig. 17 Anti-vascular endothelial growth factor therapeutics market: Product movement analysis
  • Fig. 18 Eylea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Lucentis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Beovu market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Vabysmo market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Anti-vascular endothelial growth factor therapeutics market: Disease outlook and key takeaways
  • Fig. 24 Anti-vascular endothelial growth factor therapeutics market: Disease movement analysis
  • Fig. 25 Macular edema market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Diabetic retinopathy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Retinal vein occlusion market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Age-related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Myopic choroidal neovascularization market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Anti-vascular endothelial growth factor therapeutics market revenue, by region, 2024 & 2030 USD Million
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 U.S. anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Prevalence of Diabetic Retinopathy (DR) in 2021, in U.S., in Million
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Mexico anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 UK anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Germany anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 France anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Spain anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Italy anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Denmark anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Sweden anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Norway anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Japan anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 China anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 India anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Australia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Thailand anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Korea anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Brazil anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Argentina anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamic
  • Fig. 87 Kuwait anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Rest of MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Company/competition categorization
  • Fig. 90 Company market share analysis, 2024
  • Fig. 91 Strategy mapping
目次
Product Code: GVR-4-68038-346-1

Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth & Trends:

The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 12.90 billion by 2030, registering a CAGR of -2.35% over the forecast period, according to a new report by Grand View Research, Inc. Increased funding for R&D of anti-VEGF therapeutics to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products coupled with the increasing geriatric population that is susceptible to develop ophthalmic diseases is expected to propel the market growth over the forecast period.

According to the United Nations Department of Economic and Social Affairs data, the global elderly population (aged 60 years and above) was around 703 million in 2019. The share of the population aged 65 years and above was 6%, which increased to 9% in 2019. The aging population, based on countries, was around 68.7 million in Africa, 549.2 million in Asia, 183 million in Europe, 78.4 million in North America, and more than 76 million in Latin America & other regions in 2017. Hence, the increasing geriatric population is anticipated to drive the market.

The lack of reimbursement policies in developing regions is creating an opportunity for cost-effective novel molecules. In addition, ophthalmologists switching to more effective newly launched drugs has compelled companies to invest in R&D to maintain their industry position. The interest of investigators on biosimilar of existing drugs is a major trend in the pipeline of anti-VEGF therapeutics.

Moreover, companies are developing various formulations and drug delivery systems that may increase the adoption of these therapies. For instance, F. Hoffmann La Roche Ltd. is developing the port delivery system-RG6321 (Ranibizumab)-which is currently undergoing a phase III clinical trial. It is an eye implant that is refillable and continuously delivers a customized formulation of ranibizumab over a period of months.

Loss of patent protection is likely to have a negative impact on the market growth and has led big pharma companies to consider new revenue streams. However, this is creating an emerging market for biosimilar drug producers in the space. This rising competition is anticipated to impede market growth. However, the launch of novel products with a competitive advantage is anticipated to lower the impact of the restraint during the forecast period.

Anti-vascular Endothelial Growth Factor Therapeutics Market Report Highlights:

  • In 2024, Age-related Macular Degeneration (AMD) accounted for the largest revenue share and is anticipated to maintain its dominance over the forecast period
  • Eylea dominated the product segment with the largest market share of 61.9% in 2024. Eylea (aflibercept), developed by Regeneron Pharmaceuticals in collaboration with Bayer, has been a foremost anti-VEGF therapy for treating retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO
  • North America anti-vascular endothelial growth factor therapeutics market dominated the global industry and accounted for 65.71% of revenue share in 2024, which can be attributed to the increasing prevalence of eye-related conditions such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and macular edema

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Disease outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Advancements in drug delivery and development
      • 3.2.1.3. Rising awareness about early diagnosis and treatment of ocular disorders
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of anti-VEGF therapeutics
      • 3.2.2.2. Potential side effects and safety concerns
  • 3.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Movement Analysis
  • 4.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Eylea
    • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.6. Lucentis
    • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.7. Beovu
    • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.8. Vabysmo
    • 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Movement Analysis
  • 5.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Macular Edema
    • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6. Diabetic Retinopathy
    • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7. Retinal Vein Occlusion
    • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.8. Age-related Macular Degeneration
    • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.9. Myopic Choroidal Neovascularization
    • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company overview
    • 7.4.1. Regeneron Pharmaceuticals, Inc.
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bayer AG
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. F. Hoffmann-La Roche Ltd.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Biogen
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Pfizer, Inc.
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Coherus BioSciences, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amgen, Inc.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Bausch Health Companies, Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Viatris, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives